Wednesday, June 10, 2026
🇺🇸 FDA

biotech · Major Depressive Disorder · Schizophrenia · NBIX

NEUROCRINE BIOSCIENCES

NEUROCRINE BIOSCIENCES INC

NEUROCRINE BIOSCIENCES clinical programs — 79 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
6027 Edgewood Bend Ct, San Diego, California 92130, US HQ
1992 Founded
2,307 Employees
Public company Type
NBIX · NYSE Ticker
Company details
Status
Public
HQ
6027 Edgewood Bend Ct, San Diego, California 92130, US
Founded
1992
Employees
2,307
Programs
79
Drugs
28
Patents
111
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

NEUROCRINE BIOSCIENCES projects

79 ClinicalTrials.gov programs sponsored by NEUROCRINE BIOSCIENCES.

NEUROCRINE BIOSCIENCES has 79 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

79 programs

Clinical programs

Page 1 of 2

  1. Chronocort®

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    5 trials

  2. Crinecerfont

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    4 trials

  3. Hydrocortisone

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    2 trials

  4. Indiplon

    NEUROCRINE BIOSCIENCES INC

    Insomnia

    phase 3 small molecule terminated

    1 trial

  5. Infacort®

    NEUROCRINE BIOSCIENCES INC

    Adrenal Insufficiency

    phase 3 small molecule completed

    4 trials

  6. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  7. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  8. NBI-1065845-MDD3024

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  9. NBI-1065845-MDD3025

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  10. NBI-1065845-MDD3026

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  11. NBI-1065845-MDD3027

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  12. NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    5 trials

  13. NBI-1117568, NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia, Schizophrenia

    phase 3 small molecule active

    1 trial

  14. NBI-1117568-SCZ3030

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  15. NBI-34060

    NEUROCRINE BIOSCIENCES INC

    Insomnia

    phase 3 small molecule terminated

    1 trial

  16. NBI-74788-CAH2006

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  17. NBI-74788-CAH3003

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  18. NBI-98854

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 3 small molecule completed

    6 trials

  19. NBI-98854-ATS3019

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  20. Placebo

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  21. Placebo

    NEUROCRINE BIOSCIENCES INC

    Dyskinesia

    phase 3 small molecule completed

    1 trial

  22. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 3 small molecule completed

    2 trials

  23. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Chorea, Huntington

    phase 3 small molecule active

    3 trials

  24. Chronocort

    NEUROCRINE BIOSCIENCES INC

    Primary Adrenal Insufficiency

    phase 2 small molecule completed

    1 trial

  25. Crinecerfont

    NEUROCRINE BIOSCIENCES INC

    CAH - Congenital Adrenal Hyperplasia

    phase 2 small molecule completed

    1 trial

  26. Hydrocortisone Modified Release Capsules

    NEUROCRINE BIOSCIENCES INC

    Endocrine Disease

    phase 2 small molecule completed

    1 trial

  27. Luvadaxistat

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  28. NBI-1065890

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 2 small molecule active

    1 trial

  29. NBI-1070770

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  30. NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Bipolar I Disorder

    phase 2 small molecule active

    1 trial

  31. NBI-1117570

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial

  32. NBI-1117570-SCZ2035

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial

  33. NBI-5788

    NEUROCRINE BIOSCIENCES INC

    Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  34. NBI-74788

    NEUROCRINE BIOSCIENCES INC

    Congenital adrenal hyperplasia (CAH)

    phase 2 small molecule active

    1 trial

  35. NBI-74788

    NEUROCRINE BIOSCIENCES INC

    CAH - Congenital Adrenal Hyperplasia

    phase 2 small molecule completed

    1 trial

  36. NBI-827104

    NEUROCRINE BIOSCIENCES INC

    Epileptic Encephalopathy

    phase 2 small molecule terminated

    2 trials

  37. NBI-827104

    NEUROCRINE BIOSCIENCES INC

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  38. NBI-921352

    NEUROCRINE BIOSCIENCES INC

    Focal Onset Seizure

    phase 2 small molecule completed

    2 trials

  39. NBI-921352

    NEUROCRINE BIOSCIENCES INC

    SCN8A Developmental and Epileptic Encephalopathy Syndrome

    phase 2 small molecule active

    2 trials

  40. NBI-98854

    NEUROCRINE BIOSCIENCES INC

    Tourette Syndrome

    phase 2 small molecule terminated

    4 trials

  41. Placebo

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  42. Placebo

    NEUROCRINE BIOSCIENCES INC

    Anhedonia

    phase 2 small molecule completed

    1 trial

  43. TAK-041

    NEUROCRINE BIOSCIENCES INC

    Stable Schizophrenia

    phase 2 small molecule completed

    1 trial

  44. TAK-831

    NEUROCRINE BIOSCIENCES INC

    Friedreich Ataxia

    phase 2 small molecule completed

    1 trial

  45. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Tourette Syndrome

    phase 2 small molecule completed

    4 trials

  46. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Obsessive-Compulsive Disorder

    phase 2 small molecule active

    1 trial

  47. Valbenazine Oral Capsule

    NEUROCRINE BIOSCIENCES INC

    Trichotillomania (Hair-Pulling Disorder)

    phase 2 small molecule active

    1 trial

  48. interleukin-4 PE38KDEL cytotoxin

    NEUROCRINE BIOSCIENCES INC

    Brain and Central Nervous System Tumors

    phase 2 mab completed

    1 trial

Frequently asked questions

How many clinical projects does NEUROCRINE BIOSCIENCES have?

79 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.